ICUHealthcare · BiotechnologyICU Stock Forecast: Seastar Medical Holding Corp. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Seastar Medical Holding Corp. hold a median 12-month price target of $10 — +213.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ICU stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Seastar Medical Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (91): Smaller than most of the companies we track.
Value (11): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own Seastar Medical Holding Corp. — and when they’d sell — is the membership.
ICU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ICU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +213.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Maxim Group | Maintains | Buy | $6.00 → $8.00 |
| 20 Apr 2023 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ICU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Seastar Medical Holding Corp. (ICU) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.5×
- Price / sales
- 8.7×
- Price / book
- 1.7×
- EV / EBITDA
- −0.3×
Cheaper than 80% of US stocks
Cheaper than 16% of US stocks
Cheaper than 51% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- 68.9%
- Earnings growth (YoY)
- —
- Gross margin
- 90.7%
- Operating margin
- −727.9%
- Net margin
- 95.7%
Higher than 91% of US stocks
Higher than 97% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
- Return on equity
- −302.0%
- Return on assets
- −79.2%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 4% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ICU vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ICU appears on the weeks it earns a place.
Frequently asked questions about ICU stock
What is the ICU stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Seastar Medical Holding Corp. have a median 12-month price target of $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ICU stock a buy right now?
Of the 1 analysts covering Seastar Medical Holding Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seastar Medical Holding Corp. 30 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ICU?
As at 1 Aug 2026, Seastar Medical Holding Corp. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).
Will ICU stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +213.0% from the last close, and Ticker Nerd's factor model ranks Seastar Medical Holding Corp. 30 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ICU stock forecast for 2030?
No analyst covering Seastar Medical Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
How has ICU stock performed over the past year?
Seastar Medical Holding Corp. returned -51.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Seastar Medical Holding Corp. do?
SeaStar Medical Holding Corporation is a biotechnology company headquartered in Denver, Colorado, specializing in the development and commercialization of medical devices for critically ill patients. The company operates through its patented Selective Cytopheretic Device (SCD) technology platform, which is designed to address life-threatening conditions in acute care settings.
About Seastar Medical Holding Corp.
SeaStar Medical Holding Corporation is a biotechnology company headquartered in Denver, Colorado, specializing in the development and commercialization of medical devices for critically ill patients. The company operates through its patented Selective Cytopheretic Device (SCD) technology platform, which is designed to address life-threatening conditions in acute care settings. Its lead commercial product is QUELIMMUNE (SCD-PED) therapy, which received FDA approval under a Humanitarian Device Exemption for treating acute kidney injury due to sepsis in critically ill pediatric patients undergoing renal replacement therapy. The company focuses on bringing innovative therapeutic solutions to market within the surgical and medical instruments sector, serving healthcare providers and patients in need of advanced treatment options for severe acute conditions.
CEO Mr. Eric Schlorff · 17 employees · United States · https://seastarmedical.com